Skip to content Skip to footer
Subscribe Now
Viewpoints_Wehkamp Shares
VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shared his views on the data from 13 P-II & III studies of Stelara (ustekinumab) for the treatment of IBD and other approved indications Shots: The company has reported the data from 13 P-II & III studies, including 6 studies…
November 24, 2021

Read more

Viewpoints_Daniel A. de Boer
VIEWPOINTS

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen for the Treatment of Leber Congenital Amaurosis (LCA10)

In an interview with PharmaShots, Daniel A. de Boer, Founder, and CEO at ProQR shared his views on the P-II/III Illuminate study of sepofarsen for the treatment of leber congenital amaurosis (LCA10) Shots: The ongoing P-II/III Illuminate study evaluates sepofarsen in 36 adults and children aged ≥8yrs. with LCA10. The results are expected in late Q1 or early Q2’22 In the P-I/II clinical…
November 23, 2021

Read more

Viewpoints_Chris Arendt
VIEWPOINTS

PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLC Shots: The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitor The results showed…
November 22, 2021

Read more

Viewpoints_Paul Brennan
VIEWPOINTS

PharmaShots Interview: NervGen’s Paul Brennan Shares Insights on NVG-291 and its Interim Data for the Treatment of Neurodegenerative Diseases

In an interview with PharmaShots, Paul Brennan, President, CEO & Director at NervGen shared his views on the interim data of NVG-291 for the treatment of Neurodegenerative Diseases Shots: The P-I clinical trials evaluate NVG-291 vs PBO in healthy volunteers with neurodegenerative diseases such as AD and MS. The interim results were presented at ANA 146th annual meeting The interim…
November 17, 2021

Read more

Viewpoints_Christopher J. Calhoun
VIEWPOINTS

PharmaShots Interview: Paracrine’s Christopher J. Calhoun Shares Insight on the First Autologous, Device-Based Cell Therapy Platform

In an interview with PharmaShots, Christopher J. Calhoun, President & CEO at Paracrine shared his views on the transforming diabetes treatment with the first autologous, device-based cell therapy platform Shots: The company has developed the first autologous, device-based cell therapy platform which is ideally positioned to address conditions with underlying integers Paracrine is a one-time, completely natural procedure that…
November 16, 2021

Read more

Viewpoints_Jan van de Winkel
VIEWPOINTS

PharmaShots Interview: Genmab’s Jan van de Winkel Shares Insight on the Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer

In an interview with PharmaShots, Jan van de Winkel, co-founder, President, and CEO at Genmab shared his views on the US FDA's Accelerated Approval of Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer Shots: Genmab and Seagen have reported the US FDA's accelerated approval which is based on the P-II innovaTV 204 clinical trials evaluating tisotumab vedotin in…
November 15, 2021

Read more

Viewpoints_Lloyd Miller
VIEWPOINTS

PharmaShots Interview: Janssen’s Lloyd Miller Shares Insight on the Data of Tremfya (guselkumab) Presented at EADV 2021

In an interview with PharmaShots, Lloyd Miller, MD, Ph.D., Vice President, Immunodermatology Disease Area Leader at Janssen shares his views on the data presented at EADV 2021 about patients who switch to Tremfya (guselkumab) from Humira (adalimumab) in P-III VOYAGE 1 & 2 trials for PsO & also highlighting the P-III DISCOVER-1 & 2 trial for PsA Shots: The P-III VOYAGE 1 &…
November 10, 2021

Read more

Viewpoints_Garret Hampton
VIEWPOINTS

PharmaShots Interview: Thermo Fisher Scientific Garret Hampton Shares Insight on the Multiyear Agreement with AstraZeneca for NGS-based CDx

In an interview with PharmaShots, Garret Hampton, President of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific share his views on multiyear agreement with AstraZeneca to co-develop NGS-based CDx for targeted therapies Shots: The collaboration will expand AstraZeneca’s portfolio of targeted therapies for cancer & other diseases. Thermo Fisher currently offers the NGS CDx solution which is approved…
November 9, 2021

Read more

Load more